Dupixent and Eosinophilic Disorders: What Patients Should Know

Medically reviewed by licensed healthcare professionals · Legally reviewed by mass tort litigation specialists · Last updated: March 2026

Dupixent is FDA-approved to treat eosinophilic esophagitis (EoE) and is used off-label for other eosinophil-related conditions. However, the drug's label also carries a warning about eosinophilic conditions, creating a complex picture for patients and doctors.

What Are Eosinophils?

Eosinophils are a type of white blood cell associated with the type 2 inflammatory pathway — the same pathway that drives conditions like atopic dermatitis, asthma, and nasal polyps. In healthy individuals, eosinophils play a role in fighting certain infections. In allergic and inflammatory diseases, they can become overactive and accumulate in tissues, causing damage.

Dupixent's Dual Role

Treatment for Eosinophilic Disorders: By blocking IL-4 and IL-13, Dupixent can reduce the overproduction and activation of eosinophils. This is why it is an effective treatment for eosinophilic esophagitis (EoE), where eosinophils infiltrate the esophagus, and eosinophilic phenotype asthma.

Warning About Eosinophilic Conditions: The official Dupixent prescribing information includes a warning about eosinophilic conditions. It notes that patients with pre-existing eosinophilic conditions may experience a worsening of their condition while on Dupixent. It also states that "cases of eosinophilic pneumonia, and cases of vasculitis consistent with eosinophilic granulomatosis with polyangiitis (EGPA) were reported" in patients during clinical development.

The Potential Mechanism: Unmasking vs. Causing

The leading theory for why Dupixent might be associated with new or worsening eosinophilic conditions is "unmasking." Many patients with severe asthma or atopic dermatitis are treated with oral corticosteroids (like prednisone) before starting Dupixent. Oral corticosteroids are powerful, systemic drugs that suppress all inflammation, including eosinophilic inflammation.

When a patient starts Dupixent, they are often able to significantly reduce or stop their oral corticosteroid use. The theory is that Dupixent may not be causing a new eosinophilic condition, but rather, by allowing the patient to come off the systemic steroids, it is "unmasking" an underlying eosinophilic disorder (like EGPA) that was previously being suppressed by the prednisone.

Regardless of the mechanism — unmasking or direct causation — the emergence of a serious condition like EGPA after starting Dupixent is a significant adverse event that may have legal implications.

What is EGPA?

Eosinophilic granulomatosis with polyangiitis (formerly Churg-Strauss syndrome) is a rare but serious autoimmune disease characterized by inflammation of small and medium-sized blood vessels (vasculitis). It can affect multiple organ systems, including the lungs, nerves, skin, and heart. A diagnosis of EGPA after starting Dupixent is a serious event that requires immediate medical attention, typically from a rheumatologist.

What Patients Should Monitor

Patients starting Dupixent, especially those with severe asthma who are tapering off oral steroids, should be monitored by their doctors for signs and symptoms of eosinophilic complications, including:

• Worsening respiratory symptoms
• Rash or purplish spots on the skin (vasculitic rash)
• Fever and flu-like symptoms
• Numbness, tingling, or pain in the hands or feet (peripheral neuropathy)
• Severe sinus pain or pressure

Blood tests to monitor eosinophil counts (a complete blood count with differential) are often performed before and during Dupixent therapy.